Dr. Utsab Debnath

Designation and Department& School:

Total years in experience: Research Experience – 10 years; Post PhD experience – 5 years

Papers published in journals: 19

Papers presented in conferences: 01

Citations: 127 (https://scholar.google.co.in/citations?user=fOGSjYIAAAAJ&hl=en)

Academic Background (Degrees, University Name & Year of Passing):

Pharm – West Bengal University of Technology, 2008

Pharm (Pharmaceutical Chemistry) – West Bengal University of Technology, 2010

D (Pharmaceutical Chemistry) – CSIR- Central Drug Research Institute (Registration from Integral University), 2016

Career Graph:

Honours and Achievements:

GPAT Qualified in 2010

CSIR-Direct SRF awarded in 2011

SERB-NPDF awarded in 2017

Research:

Contribution:

During PhD work:

Designed and synthesize different thiazolidine-4-one and piperazine basedanalogues as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-1.

Molecular modelling studies including docking, 3D-QSAR, vHTS, Molecular Dynamics etc. to design newpyridin-2-one and related analogues as NNRTIs.

Designed and synthesize a new scaffold via molecularmodelling to inhibit the activity of integrase

An in-silico exploration for new antimalarials: Arylsulfonyloxy acetimidamides as prospective agents. Apart from my PhD work, I made significant research contributions in other diseases like Leashmania and Cancer.

Post-PhD work:

Designed and synthesis of tubulin and topoisomerase II inhibitors fordeveloping new chemical entities as anti-cancer agents

Investigated new allicin analogues to understand the structure activity relationship (SAR) against caspase-3 enzyme.

Design and synthesis of Aryl quinolinyl hyadrazone derivatives as anti-inflammatory agents that inhibit TLR4 activation in the macrophages.

Conformational perturbation of SARS-CoV-2 spike protein by N-acetyl cysteine (NAC) to get aprobable strategy to combat COVID-19.

Interests:

Identification of novel targets of infectious diseases and cancer by various in silico methods followed by implementation of newcomputational methods to screen large databases of heterocyclic molecules for the development of new inhibitorsagainst the target enzyme.

Hit to lead formation followed by lead optimization via organic synthesis.

Structure activity relationship (SAR) based on Molecular docking &QSAR method.

Recent Publications: (2015-2020)

Year 2020

Debnath U, Dewaker V, Prabhakar Y. S., Bhattacharyya P, Mandal A. Conformational Perturbation ofSARS-CoV-2 Spike Protein Using N-Acetyl Cysteine, a Molecular Scissor: A Probable Strategy to CombatCOVID-19. ChemRxiv. 2020. Preprint.https://doi.org/10.26434/chemrxiv.12687923.v1

IslamK, PalK,Debnath U, BashaRS, KhanAT, JanaK, MisraAK. Anti-cancer potential of (1, 2-dihydronaphtho [2, 1-b] furan-2-yl) methanone derivatives.  Bioorganic & Medicinal Chemistry Letters. 30 (20), 127476.https://doi.org/10.1016/j.bmcl.2020.127476

Mandal SK, Debnath U, Kumar A, Thomas S, Mandal S, Choudhury MD, Palit P. Natural Sesquiterpene Lactones in the Prevention and Treatment of Inflammatory Disorders and cancer: A Systematic Study of this Emerging Therapeutic Approach based on Chemical and Pharmacological Aspect. Letters in Drug Design & Discovery, 17, 2020, pp. 1102-1116(15). https://doi.org/10.2174/1570180817999200421144007

Year 2019

Bhaumik I, Pal K, Debnath U, Jana K, Misra A. K.; Natural product inspired Allicin analogues a novel anticancer agent

Debnath U, Mukherjee S, Joardar N, Jana K, Sinha Babu S.P., Misra A. K.; Aryl quinolinyl hyadrazonederivatives as anti-inflammatory agents that inhibit TLR4 activation in the macrophages. Eur J Pharm. Sci. 2019, 134:102-115.https://doi.org/10.1016/j.ejps.2019.04.016

Year 2018

 Kondaparla S*, Debnath U*, Soni A, Dola V, Sinha M, Srivastava K, Puri S, and Katti S. B. Katti;Synthesis, Biological Evaluation and Molecular Modeling Studies of Chiral Chloroquine Analogues asAntimalarial Agents. Antimicrob Agents Chemother. 2018, 62(12): e02347-17 (*equal contribution)DOI: 10.1128/AAC.02347-17

Kamil R. F., Debnath U., Verma S., Prabhakar Y.S.; Identification of adjacent NNRTI binding pocket inmulti-mutated HIV1-RT Enzyme Model, An in-silico study. Curr HIV Res. 2018; 16(2): 121-129.https://doi.org/10.2174/1570162X16666180412165004

Das N, Bhattacharya A, Kumar Mandal S, Debnath U, Dinda B, Mandal S C, Kumar Sinhamahapatra P,Kumar A, Dutta Choudhury M, Maiti S, Palit P. Ichnocarpus frutescens (L.) R. Br. root derived phytosteroids defends inflammation and algesia by pulling down the pro-inflammatory and nociceptivepain mediators: An in-vitro and in-vivo appraisal. Steroids. 2018; (139): 18-27.https://doi.org/10.1016/j.steroids.2018.09.005

Pyne P, Alam M, Rameez MJ, Mandal S, Sar A, Mondal N, Debnath U, Mathew B, Misra A K,MandalAK, Ghosh W; Homologs from sulfur oxidation (Sox) and methanol dehydrogenation (Xox) enzymesystems collaborate to give rise to a novel pathway of chemolithotrophic tetrathionate oxidation. MolMicrobiol. 2018; 109(2): 169-191. 

https://doi.org/10.1111/mmi.13972

Year 2017

Debnath U, Singh P, Gupta S K, Katti S.B.; N-hydroxy substituted 2-aryl acetamide analogues:new class of integrase inhibitors. Chem Biol Drug Des. 2017; 90(4):527-534. 

https://doi.org/10.1111/cbdd.12974

Deshpande S, Shivahare R, Debnath U, Sane S. A., Srivastava K, Haq W., Puri S. K., Gupta S, Katti S. B.;Synthesis, Antileishmanial and Antiplasmodial Activity of 7-trifluromethyl Substituted 4-Aminoquinoline Derivatives. The natural products journal. 2017, 7(2): 137-143.

Year 2016

Saxena R, Gupta G, Manohar M, Debnath U, Popli P, Prabhakar Y.S., Konwar R, Kumar S, Kumar A,Dwivedi A; Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl)spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53function. Int J Biochem Cell Biol. 2016, 70:105-17.

https://doi.org/10.1016/j.biocel.2015.11.003

Year 2015

Kushwaha R N, Debnath U, Singh P, Saxena R, Gupta S K, Tripathi R K, Siddiqui H H, Katti S. B.; NewPiperazine-Derived NNRTIs as Anti-HIV Agent: Synthesis, Biological Evaluation and MolecularDocking Studies. Indo American Journal of Pharm Research, 2015: 5(01).

Debnath U, Verma S, Singh P, Rawat K, Gupta S K, Tripathi R K, Siddiqui H H, Katti S. B., PrabhakarY. S.; Synthesis, Biological Evaluation and Molecular Modeling studies of New 2,3-diheteroarylthiazolidin-4-ones as NNRTIs. Chem Biol Drug Des. 2015. 86(5): 1285-91.https://doi.org/10.1111/cbdd.12591

Verma S, Debnath U, Agarwal P, Srivastava K, Prabhakar Y. S. In Silico Exploration for NewAntimalarials: Arylsulfonyloxy Acetimidamides as Prospective Agents. J Chem Inf Model. 2015,55(8):1708-19.https://doi.org/10.1021/acs.jcim.5b00392

Projects or Ph.D.s guided:Nil

Books Published: 01

Debnath U and Katti S. B.; Recent Developments in HIV-1 Integrase Inhibitors; Advances in Studies onEnzyme inhibitors, Volume 1: Anticancer and Antiviral Drugs; Nova science publishers; NY, USA. 2017Jan, pp 287-312. (ISBN: 978-1-53610-9)(ebook).

Professional Memberships/Fellowship:

SERB-NPDF (2017-2019)

Personal interests:Gardening, listen music, Playing cricket